TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation
Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Information about National Cancer Institute (NCI)-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following are examples of national and/or institutional clinical trials that are currently being conducted:
NCT04258046 (Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation): This is a phase II study to assess the safety and efficacy of trametinib in the treatment of children and adults.
Source links and citations
NCT05125471 (Cobimetinib in Extracranial Arteriovenous Malformations [COBI-AVM Study]): This is a phase II study to evaluate the safety and efficacy of cobimetinib in the treatment of children and adults.
Source links and citations
NCT05948943 (Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Variant): This is a phase II/III study of adults and children (aged 6–17 years) that will determine the dose of alpelisib in stage 1, followed by confirmation of efficacy and safety in stage 2 of the study.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice